Shares of AstraZeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug.  An advisory panel for the U.S. Food and Drug Administration late Thursday voted 6-3 against AstraZeneca's oral drug camizestrant intended for the treatment of a type of breast cancer tumor, citing concerns around trial design. The FDA generally follows the recommendations of its advisory committees, but isn't bound to.  AstraZeneca's London-listed shares fell 2% in morning trading.  The members voting against the drug's approval weren't convinced that the trial proved that early switching to camizestrant improved long-term survival rates compared to other ways of treating the disease.  Stock Chart Icon Stock chart icon AstraZeneca shares over the past 12 months. The vote was based on the Phase 3 results for the clinical trial SERENA-6 presented in 2025, which showed a 56% reduction in the risk of disease progression or death, compared to standard of care.…